ChemMedChem最新文献

筛选
英文 中文
Triflic Acid-Mediated Synthesis of 2-Sulfonamido Substituted 4H-Chromenes From para-Quinone Methides and Their Antiplasmodial Activity 三羧酸介导对醌类化合物合成2-磺胺取代的4h -铬及其抗疟原虫活性。
IF 3.5 4区 医学
ChemMedChem Pub Date : 2026-10-05 DOI: 10.1002/cmdc.70517
Farman M. Abbasi, Aritra Ghosh,  Siddhant, Ashan Manhas, Niti Kumar, Sanjay Batra
{"title":"Triflic Acid-Mediated Synthesis of 2-Sulfonamido Substituted 4H-Chromenes From para-Quinone Methides and Their Antiplasmodial Activity","authors":"Farman M. Abbasi,&nbsp;Aritra Ghosh,&nbsp; Siddhant,&nbsp;Ashan Manhas,&nbsp;Niti Kumar,&nbsp;Sanjay Batra","doi":"10.1002/cmdc.70517","DOIUrl":"10.1002/cmdc.70517","url":null,"abstract":"<p>An expedited synthesis of 2-sulfonamido-substituted 4<i>H</i>-chromene derivatives via reaction between <i>para</i>-quinone methides and ynamides in the presence of triflic acid at room temperature is described. Most of the synthesized compounds displayed potent antiplasmodial activity against both the chloroquine-sensitive and -resistant strains of <i>Plasmodium falciparum</i> with a good selectivity index.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":"21 19","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149101818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Discovery and Characterization of Novel Piperidine Derivatives as Potent Cytochrome P450 17A1 Inhibitors for Prostate Cancer Therapy 新型哌啶衍生物作为前列腺癌治疗中有效的细胞色素P450 17A1抑制剂的发现和表征。
IF 3.5 4区 医学
ChemMedChem Pub Date : 2026-10-04 DOI: 10.1002/cmdc.70336
Angelika Grudzińska, Jibira Yakubu, Chiara Vigato, Therina du Toit, Gaia Vanzetti, Radosław Zan, Donatella Boschi, Simonetta Oliaro-Bosso, Fredrik Björkling, Flemming Steen Jørgensen, Amit V. Pandey, Tomasz M. Wróbel
{"title":"Discovery and Characterization of Novel Piperidine Derivatives as Potent Cytochrome P450 17A1 Inhibitors for Prostate Cancer Therapy","authors":"Angelika Grudzińska,&nbsp;Jibira Yakubu,&nbsp;Chiara Vigato,&nbsp;Therina du Toit,&nbsp;Gaia Vanzetti,&nbsp;Radosław Zan,&nbsp;Donatella Boschi,&nbsp;Simonetta Oliaro-Bosso,&nbsp;Fredrik Björkling,&nbsp;Flemming Steen Jørgensen,&nbsp;Amit V. Pandey,&nbsp;Tomasz M. Wróbel","doi":"10.1002/cmdc.70336","DOIUrl":"10.1002/cmdc.70336","url":null,"abstract":"<p>Castration-resistant prostate cancer relies on intratumoral androgen synthesis mediated by cytochrome P450 17A1 (CYP17A1). Treatment with the only clinically used CYP17A1 inhibitor, abiraterone, is limited by resistance and side effects, underscoring the urgent need for new CYP17A1 inhibitors with greater selectivity and improved safety profiles. In response to this challenge, we designed, synthesized, and biologically evaluated 30 novel piperidine derivatives. All compounds were initially screened in the H295R cell line to assess their inhibitory activity toward both CYP17A1 and off-target CYP21A2. Compounds were further evaluated in cell viability assays using prostate cancer cells and a normal prostate cell line. The most potent and selective compounds were subjected to further biological studies: IC<sub>50</sub> determination, steroid profiling, cell migration assay, aldo–keto reductase family 1 member C3 inhibition assays, absorption, distribution, metabolism, and excretion prediction, and solubility testing. Several compounds emerged as the most active and selective leads, highlighting their potential for pharmaceutical development.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":"21 19","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149101722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel (Azolo)Pyrimidine Derivatives as Dual Modulators of NO and IL-6 in Murine Macrophages and Human Monocytes 新型(偶氮)嘧啶衍生物在小鼠巨噬细胞和人单核细胞中作为NO和IL-6的双重调节剂。
IF 3.5 4区 医学
ChemMedChem Pub Date : 2026-10-04 DOI: 10.1002/cmdc.70485
Irina G. Ovchinnikova, Olga V. Fedorova, Nikolay A. Rasputin, Grigory A. Kim, Elena S. Filatova, Polina K. Titova, Denis A. Babkov, Elena V. Sokolova, Andrey V. Lukyanov, Roman D. Danilov, Gennady L. Rusinov, Alexander A. Spasov, Egor V. Verbitskiy, Valery N. Charushin
{"title":"Novel (Azolo)Pyrimidine Derivatives as Dual Modulators of NO and IL-6 in Murine Macrophages and Human Monocytes","authors":"Irina G. Ovchinnikova,&nbsp;Olga V. Fedorova,&nbsp;Nikolay A. Rasputin,&nbsp;Grigory A. Kim,&nbsp;Elena S. Filatova,&nbsp;Polina K. Titova,&nbsp;Denis A. Babkov,&nbsp;Elena V. Sokolova,&nbsp;Andrey V. Lukyanov,&nbsp;Roman D. Danilov,&nbsp;Gennady L. Rusinov,&nbsp;Alexander A. Spasov,&nbsp;Egor V. Verbitskiy,&nbsp;Valery N. Charushin","doi":"10.1002/cmdc.70485","DOIUrl":"10.1002/cmdc.70485","url":null,"abstract":"<p>Small molecules that simultaneously suppress nitric oxide (NO) and interleukin‑6 (IL‑6) offer a strategy to alleviate pathological inflammation. Building on our previous work with aryl‑substituted azaheterocycles, we synthesized 33 new pyrimidine and azolopyrimidine derivatives bearing amino, amide, hydroxyl, or halide groups to enhance hydrogen‑bonding capacity and improve inhibitory activity against both mediators. Screening in C57BL/6J mouse peritoneal macrophages identified nine compounds that markedly inhibited NO production at 50 µM. Two leads—triazolo[1,5‑a]pyrimidine 12bc and dihydropyrimidine carboxamide 7a—emerged as potent dual inhibitors. Compound 7a showed IC<sub>50</sub> values of 0.47 µM (NO) and 0.1 µM (IL‑6); 12bc gave 8.66 µM (NO) and 0.85 µM (IL‑6), both with acceptable cytotoxicity. In human PBMC‑derived monocytes, both compounds dose‑dependently suppressed LPS‑induced IL‑6 secretion; 12bc was slightly more potent, reducing IL‑6 to near‑baseline at 100 µM, comparable to dexamethasone. In an LPS/ATP pyroptosis model, they protected monocytes from inflammatory death, with 12bc nearly restoring normal cell morphology. Docking studies into mouse iNOS and IL‑6 suggested plausible binding modes and structure–activity relationships. These (azolo)pyrimidine scaffolds represent promising leads for safe, dual‑acting anti‑inflammatory agents.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":"21 19","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149101897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Discrepancy in Reported and Observed Monoacylglycerol Lipase Inhibition of Aryl Formyl Piperidine Containing Potent and Highly Selective Monoacylglycerol Lipase Inhibitor 含有强效和高选择性单酰基甘油脂肪酶抑制剂的芳酰甲酰基哌啶对单酰基甘油脂肪酶抑制作用的报道和观察的差异。
IF 3.5 4区 医学
ChemMedChem Pub Date : 2026-10-04 DOI: 10.1002/cmdc.70525
Juha R. Savinainen, Praveen Kumar Singh, Jari Yli-Kauhaluoma, Jayendra Z. Patel
{"title":"Discrepancy in Reported and Observed Monoacylglycerol Lipase Inhibition of Aryl Formyl Piperidine Containing Potent and Highly Selective Monoacylglycerol Lipase Inhibitor","authors":"Juha R. Savinainen,&nbsp;Praveen Kumar Singh,&nbsp;Jari Yli-Kauhaluoma,&nbsp;Jayendra Z. Patel","doi":"10.1002/cmdc.70525","DOIUrl":"10.1002/cmdc.70525","url":null,"abstract":"<p>Zhi et al. reported compound <b>36</b> as a potent reversible inhibitor of human recombinant monoacylglycerol lipase (hrMAGL; IC<sub>50</sub> = 15 nM) with excellent selectivity over other targets. To develop potential PET tracers for imaging MAGL, we synthesized compound <b>36</b> as a reference compound. Surprisingly, we observed a significant discrepancy between the reported potency and our findings in two well-established in vitro assays. Compound <b>36</b> exhibited no inhibition of endocannabinoid hydrolysis in HEK293 lysates overexpressing human MAGL in a glycerol-based assay at 1 μM. In the competitive ABPP assay, it appeared completely inactive inhibiting MAGL in mouse whole-brain proteome even at 100 μM. In addition, eight structural analogs (<b>2</b>–<b>9</b>) of compound <b>36</b> also failed to show any significant MAGL inhibition. Interestingly, when the synthetic substrate 4-nitrophenyl acetate, also used by Zhi et al., was employed, compound <b>36</b> inhibited MAGL more effectively than in glycerol-based assay, with an IC<sub>50</sub> value of 143 nM, being almost 10-fold less potent than reported. In our reversibility assay, compound <b>36</b> exhibited measurable MAGL inhibition only at a concentration of 100 μM. In summary, this study contradicts the earlier report and therefore, compound <b>36</b> should be used with caution as a research tool in studies exploring MAGL inhibition.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":"21 19","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13635760/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149101728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Capturing Hu Antigen R Domain Closure Through Supervised Molecular Dynamics Simulations 通过监督分子动力学模拟捕获胡抗原R结构域闭合。
IF 3.5 4区 医学
ChemMedChem Pub Date : 2026-10-04 DOI: 10.1002/cmdc.70523
Chiara Cavastracci Strascia, Andrea Dodaro, Gianluca Novello, Silvia Menin, Mattia Sturlese, Veronica Salmaso, Stefano Moro
{"title":"Capturing Hu Antigen R Domain Closure Through Supervised Molecular Dynamics Simulations","authors":"Chiara Cavastracci Strascia,&nbsp;Andrea Dodaro,&nbsp;Gianluca Novello,&nbsp;Silvia Menin,&nbsp;Mattia Sturlese,&nbsp;Veronica Salmaso,&nbsp;Stefano Moro","doi":"10.1002/cmdc.70523","DOIUrl":"10.1002/cmdc.70523","url":null,"abstract":"<p>Hu antigen R (HuR), an RNA-binding protein implicated in cancer, inflammation, and neurodegenerative disorders, represents a challenging target for drug discovery due to its large solvent-exposed RNA-binding interface and pronounced conformational flexibility. HuR contains tandem RNA recognition motifs (RRM1 and RRM2) that undergo substantial rearrangements between an apo open state and an RNA-bound closed conformation. Here, we investigated both states using molecular dynamics (MD) simulations. While the RNA-bound complex maintained a stable closed architecture, the apo form displayed extensive interdomain motions, highlighting the intrinsic flexibility of HuR. Because conventional MD simulations failed to capture the open-to-closed transition, we developed a novel application of Supervised MD (SuMD), previously employed for intermolecular recognition processes, to characterize HuR intramolecular domain closure. Using a multistep supervision protocol based on selected interdomain residue pairs, SuMD reproduced a closed conformation resembling the experimental RNA-bound structure and identified a plausible reclosure pathway. Per–residue interaction analyses revealed key contributions from the RRM1–RRM2 linker region, particularly Arg97, together with Arg136 and Arg147 of RRM2, consistent with mutagenesis data. These findings extend the applicability of SuMD to intramolecular conformational transitions, provide mechanistic insight into HuR domain closure, and offer a structural framework for identifying druggable conformational states for future HuR-targeted drug discovery.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":"21 19","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13635762/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149101758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medicinal Chemistry Aspects of Thiazole and Thiazolidine Derivatives as Fundamental Building Blocks to Design New NNRTIs Against HIV-1 Reverse Transcriptase 噻唑和噻唑烷衍生物作为设计新的抗HIV-1逆转录酶NNRTIs的基本构建模块的药物化学方面。
IF 3.5 4区 医学
ChemMedChem Pub Date : 2026-09-30 DOI: 10.1002/cmdc.70494
José Arion da Silva Moura, Matheus Vinicius Guimarães de Melo, Diane Regis Santos do Nascimento, Thaynara Paula Warren Bezerra, Mathieu Métifiot, Patricia Recordon-Pinson, Maira Galdino da Rocha Pitta, Marina Galdino da Rocha Pitta, Michelly Cristiny Pereira, Marie-Line Andreola
{"title":"Medicinal Chemistry Aspects of Thiazole and Thiazolidine Derivatives as Fundamental Building Blocks to Design New NNRTIs Against HIV-1 Reverse Transcriptase","authors":"José Arion da Silva Moura,&nbsp;Matheus Vinicius Guimarães de Melo,&nbsp;Diane Regis Santos do Nascimento,&nbsp;Thaynara Paula Warren Bezerra,&nbsp;Mathieu Métifiot,&nbsp;Patricia Recordon-Pinson,&nbsp;Maira Galdino da Rocha Pitta,&nbsp;Marina Galdino da Rocha Pitta,&nbsp;Michelly Cristiny Pereira,&nbsp;Marie-Line Andreola","doi":"10.1002/cmdc.70494","DOIUrl":"10.1002/cmdc.70494","url":null,"abstract":"<p>The therapy to treat the Human Immunodeficiency virus (HIV) and decrease the viral load has been a challenge since its discovery due to its ability to mutate, escape from drug therapies, and immunologic system. Consequently, the development of new therapies, especially potential molecules that focus on specific viral mechanisms to block viral replication, became a critical challenge in recent decades. The Reverse Transcriptase (RT) is an RNA- and DNA-dependent DNA polymerase enzyme that is responsible for transcribing viral RNA into double-stranded DNA. Non-nucleoside RT Inhibitors perform important role in HIV therapy, and they are responsible for inhibiting RT by blocking its allosteric site, which shows physico-chemical properties such as high hydrophobicity and key amino acid-to-hydrogen bond interactions. For this reason, designing new molecules with innovative heterocycles compatible with these characteristics can provide new potential inhibitors. For example, pentacyclic heterocycles like thiazole and its derivatives like thiazolidinedione, which have physico-chemical properties that can interact with the allosteric site of RT, can be a new perspective in designing new Non-nucleoside RT Inhibitors. This work reviews the scientific literature concerning these compounds and can help the design of new antiviral therapeutics.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":"21 19","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13627282/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149101838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From Undruggable to Actionable: Redefining Druggability Through Emerging Therapeutic Modalities 从不可药物到可操作:通过新兴的治疗方式重新定义药物。
IF 3.5 4区 医学
ChemMedChem Pub Date : 2026-09-29 DOI: 10.1002/cmdc.70516
Ahmed Mohsen Kamal El-sagheir
{"title":"From Undruggable to Actionable: Redefining Druggability Through Emerging Therapeutic Modalities","authors":"Ahmed Mohsen Kamal El-sagheir","doi":"10.1002/cmdc.70516","DOIUrl":"10.1002/cmdc.70516","url":null,"abstract":"<p>The concept of “undruggable” targets has long represented a major limitation in medicinal chemistry, referring to proteins and biomolecules that lack well-defined binding pockets or exhibit highly dynamic conformational behavior. However, advances in structural biology, chemical biology, and computational methodologies are rapidly expanding the scope of tractable therapeutic space. Emerging modalities, including targeted protein degradation, molecular glues, macrocycles, RNA-targeting small molecules, covalent ligands, and artificial intelligence-assisted molecular design, enable pharmacological mechanisms beyond classical occupancy-based inhibition through strategies such as induced proximity, expanded molecular recognition, covalent engagement, and RNA-level regulation. These approaches challenge the traditional binary classification of druggability and support a more context-dependent view of therapeutic accessibility. Despite this progress, significant challenges remain in optimizing pharmacokinetic properties, ensuring selectivity, minimizing toxicity, and achieving robust clinical translation. This editorial provides a mechanistic perspective on how emerging modalities are extending the boundaries of modern drug discovery.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":"21 19","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cmdc.70516","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149079037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diethylene Glycol-Linked Ring-Fused Bis-Azoles: Target-Oriented Synthesis, In Silico Screening, and Antitumor Activity 二乙二醇环融合双偶氮:靶向合成、硅筛选和抗肿瘤活性。
IF 3.5 4区 医学
ChemMedChem Pub Date : 2026-09-29 DOI: 10.1002/cmdc.70504
Sami A. Al-Hussain, Abdulrahman S. Alharbi, Zeinab A. Muhammad, Alyaa S. Abdel Halim, Magdi E. A. Zaki, Mark C. Bagley, Refaie M. Kassab
{"title":"Diethylene Glycol-Linked Ring-Fused Bis-Azoles: Target-Oriented Synthesis, In Silico Screening, and Antitumor Activity","authors":"Sami A. Al-Hussain,&nbsp;Abdulrahman S. Alharbi,&nbsp;Zeinab A. Muhammad,&nbsp;Alyaa S. Abdel Halim,&nbsp;Magdi E. A. Zaki,&nbsp;Mark C. Bagley,&nbsp;Refaie M. Kassab","doi":"10.1002/cmdc.70504","DOIUrl":"10.1002/cmdc.70504","url":null,"abstract":"<p>The target-oriented synthesis of diethylene glycol-linked bis-imidazo- and bis-thiazolo ring-fused mono-, bi-, and tricyclic derivatives was accomplished using inexpensive reagents, bis-phenacyl bromide derivative <b>4</b>, and thiosemicarbazone <b>6</b>. The diethylene glycol-linked architectures included bis(thiazolo[3,2-<i>a</i>]pyrimidinone) derivatives <b>8a,b</b>, bis(imidazo-azole) derivatives <b>12-14</b>, bis(imidazo-thiazole) derivatives <b>17,18</b>, and bis-thiazoles <b>20a-g</b>. Cytotoxic evaluation against liver, lung, colon, and prostate human tumor cell lines found remarkable selectivity to hepatocellular carcinoma (HepG2) cells. The most potent bis-imidazo- and bis-thiazolo-fused derivatives <b>8a,b</b>, <b>12</b> and <b>13</b> demonstrated cytotoxicity against HepG2 cells (IC<sub>50</sub> 6.8–17.8 µM) with exceptional selectivity (SI 5.6–14.6) compared with cisplatin (SI 2.4). Further screening of their VEGFR-2 TK and FGFR-2 TK inhibition showed that <b>8a</b> had moderate activity, whereas phenyl-substituted derivative <b>8b</b> displayed promising anti-VEGFR-2 and remarkable anti-FGFR-2 activities, with IC<sub>50</sub> 0.19 ± 0.01 and 0.03 ± 0.01 µM, respectively, compared with the reference drugs sorafenib (IC<sub>50</sub> 0.12 ± 0.01) and staurosporine (IC<sub>50</sub> 0.03 ± 0.01 µM). The inhibition of VEGFR-2 and FGFR-2 TKs was supported by molecular docking studies, with compound <b>8b</b> showing binding affinity to the VEGFR-2 and FGFR-2 ATP binding pockets. Pharmacokinetics and ADMET drug-likeness evaluation indicated that bis(thiazolo[3,2-<i>a</i>]pyrimidinone) derivatives <b>8a</b> and <b>8b</b> have drug-like properties.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":"21 19","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13624519/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149079047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hitting Coronaviruses Where It Hurts: Antiviral Strategies Targeting Viral Proteins 打击冠状病毒的伤害:针对病毒蛋白质的抗病毒策略。
IF 3.5 4区 医学
ChemMedChem Pub Date : 2026-09-29 DOI: 10.1002/cmdc.70507
Álvaro de la Cruz-Potenciano, Miguel Maldonado, María-José Camarasa, Sonia de Castro
{"title":"Hitting Coronaviruses Where It Hurts: Antiviral Strategies Targeting Viral Proteins","authors":"Álvaro de la Cruz-Potenciano,&nbsp;Miguel Maldonado,&nbsp;María-José Camarasa,&nbsp;Sonia de Castro","doi":"10.1002/cmdc.70507","DOIUrl":"10.1002/cmdc.70507","url":null,"abstract":"<p>Human coronaviruses include both endemic respiratory pathogens and highly pathogenic viruses with pandemic potential, underscoring the need for antiviral agents with activity beyond single viral species. This review focuses on selected, representative antiviral inhibitors directed against viral proteins of human coronaviruses. Accordingly, the review examines representative inhibitors targeting viral proteins essential for coronavirus infection and propagation. The discussion includes inhibitors acting at different functional levels of the viral life cycle, such as entry, genome replication, RNA processing and particle assembly, and reflects the range of molecular entities reported to date. By organizing known inhibitors according to their viral protein targets, this review provides an integrated overview of current antiviral candidates and illustrates the central role of viral proteins as points of intervention. Overall, the review aims to consolidate existing knowledge on antiviral inhibitors across human coronaviruses, offering a coherent framework for appreciating their scope and diversity.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":"21 19","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13624369/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149079128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of the Binding Affinity of Covalent Inhibitors of Cruzain and Cathepsin L Using Relative Binding Free Energy 利用相对结合自由能评价Cruzain和Cathepsin L共价抑制剂的结合亲和力
IF 3.5 4区 医学
ChemMedChem Pub Date : 2026-09-27 DOI: 10.1002/cmdc.70508
Yan Carvalho Magno, Luiz Fernando Barbosa, Maycon Vinicius Damasceno de Oliveira, Jerônimo Lameira, Carlos A. Montanari
{"title":"Assessment of the Binding Affinity of Covalent Inhibitors of Cruzain and Cathepsin L Using Relative Binding Free Energy","authors":"Yan Carvalho Magno,&nbsp;Luiz Fernando Barbosa,&nbsp;Maycon Vinicius Damasceno de Oliveira,&nbsp;Jerônimo Lameira,&nbsp;Carlos A. Montanari","doi":"10.1002/cmdc.70508","DOIUrl":"https://doi.org/10.1002/cmdc.70508","url":null,"abstract":"<p>Cysteine proteases are recognized as relevant therapeutic targets in both parasitic diseases and cancer due to their essential biological functions. Among these enzymes, cruzain from <i>Trypanosoma cruzi</i> is an important molecular target for the treatment of Chagas disease. Likewise, human cathepsin L (hCatL) is a potential target for anticancer drug development. Both enzymes share conserved catalytic features, particularly the cysteine–histidine catalytic dyad, which enables interaction with nitrile-based reversible covalent inhibitors. Here, six nitrile-derived inhibitors (<b>Neq1171.1, Neq1172.1, Neq1181.1, Neq1182.1, Neq1268, and Neq1276</b>) had their cruzain and hCatL inhibition constants, <i>K</i><sub>i</sub>, determined. Besides, we have used molecular dynamics simulation and alchemical free energy calculations for evaluating the overall relative binding free energies of these inhibitors. The calculated free energy differences closely reproduced experimental trends, confirming the reliability of the computational protocol. These findings demonstrate that thermodynamic integration is an effective strategy for predicting relative binding affinities and provides valuable molecular-level insights for the rational optimization of cysteine protease inhibitors with potential applications in Chagas disease and cancer therapy.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":"21 19","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cmdc.70508","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149068509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书